Search
Umifenovir
go.drugbank.com/drugs/DB13609Investigational[A191475] Umifenovir is currently being investigated as a potential treatment and prophylactic agent for COVID-19 caused by SARS-CoV2 infections in combination with both currently available and investigational
MW33
go.drugbank.com/drugs/DB16358ExperimentalMW33 is a recombinant fully human antibody to SARS-CoV-2.
AV-COVID-19
go.drugbank.com/drugs/DB15802InvestigationalThe monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration. … AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
Vilobelimab
go.drugbank.com/drugs/DB16416ApprovedInvestigationalVilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. It consists of mouse anti-human complement factor 5a (C5a) monoclonal binding sites (variable regions ...
Pumactant
go.drugbank.com/drugs/DB04955ExperimentalPumactant is a synthetic surfactant used for treating respiratory distress syndrome in neonates. It is a unique formulation of the naturally occurring phospholipids Dipalmitoylphosphatidycholine (DPPC) and Phosphatidyl Glycerol (PG).
Barium sulfate
go.drugbank.com/drugs/DB11150ApprovedBarium sulfate is an inorganic compound with the chemical formula BaSO4 . Barium sulfate occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation ...
Aprotinin
go.drugbank.com/drugs/DB06692ApprovedInvestigationalWithdrawnAprotinin is a protein-based drug that is also known as bovine pancreatic trypsin inhibitor (BPTI). Since it demonstrates the capacity to slow fibrinolysis, it has been employed to reduce bleeding during complex surgery such as heart and...
Mixtures: SAN. VE TİC. LTD.Goflikicept
go.drugbank.com/drugs/DB16396Investigationaltrial NCT04380519 (Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (Sars-cov